Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
- Takeda’s Pevonedistat Set to Be 1st Legally Backed Sakigake Drug
August 2, 2021
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- GMP Inspections to Be Conducted Unannounced as Basic Rule: MHLW
July 30, 2021
- Forxiga Clears PAFSC, in Line to Become Japan’s 1st CKD Drug in August
July 29, 2021
- LDP Project Team on Drug Discovery Capabilities Likely to Meet Aug. 4
July 28, 2021
- Label Revisions Ordered for AstraZeneca’s COVID-19 Vaccine; Thrombocytopenia Added to Adverse Reactions
July 28, 2021
- Panels Agree to Add Risk of Thrombocytopenia to AstraZeneca Vaccine Label
July 27, 2021
- Prioritize Alfacalcidol Supply for Non-Osteoporosis Indications: MHLW
July 27, 2021
- Spread of Regional Formularies Will Depend on “Human Relationships and Consensus-Building”: Professor
July 26, 2021
- Chuikyo Reps Fret Negative Impact of Tougher Pledge Rule, but MHLW Says It’s Conducive to Stable Supplies
July 26, 2021
- Chuikyo Roughly Approves 11 Proposals to Hone CEA System
July 26, 2021
- MHLW to Tighten “Written Pledge” Rule on Generic Listings to Thwart Supply Issues
July 26, 2021
- Japan to Discuss Approval of Individual Fertility Drugs after August
July 26, 2021
- Label Revisions Ordered for Evenity, Other Bone Disease Drugs
July 21, 2021
- Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
- Japan to Receive 50 Million More Doses of Moderna Vaccine
July 21, 2021
- New Generic Target Seems “Conservative Goal”, Dispensing Premium Revision Is a Must: Budget Examiner
July 20, 2021
- Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
- Prefectural Governors Push AstraZeneca Vaccine Use
July 20, 2021
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…